Seagen Surges on Report Merck Eyeing Purchase of Company
Comment of the Day

June 17 2022

Commentary by Eoin Treacy

Seagen Surges on Report Merck Eyeing Purchase of Company

This article by Caitlin Fichtel for Bloomberg may be of interest to subscribers.

Seagen jumps as much as 20% Friday, the most since February 2021, after Dow Jones reported that Merck is eyeing a purchase of the biotech firm, citing people familiar with the matter.

Merck gains as much as 1% Friday
Report adds that talks have been in progress for a while, although a deal is not imminent
Marketing agreement could be struck instead of full purchase
Other unnamed companies are also interested in Seagen

Eoin Treacy's view

The biotechnology sector was overtaken by vaccine mania during the pandemic. A small number of companies led by Moderna quickly grew to dominate the weighting of the sector. For 18 months the biotech index behaved more like a small number of vaccine providers, than the wide array of solutions to intransigent problems the companies it is comprised by represent. The collapse of vaccine providers, as the immediate risk from this pandemic recedes, means the biotech sector is back trading on the individual merits of its companies.

Click HERE to subscribe to Fuller Treacy Money Back to top